These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 20605870)

  • 21. Improving pediatric dosing through pediatric initiatives: what we have learned.
    Rodriguez W; Selen A; Avant D; Chaurasia C; Crescenzi T; Gieser G; Di Giacinto J; Huang SM; Lee P; Mathis L; Murphy D; Murphy S; Roberts R; Sachs HC; Suarez S; Tandon V; Uppoor RS
    Pediatrics; 2008 Mar; 121(3):530-9. PubMed ID: 18310202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral drug delivery in personalized medicine: unmet needs and novel approaches.
    Wening K; Breitkreutz J
    Int J Pharm; 2011 Feb; 404(1-2):1-9. PubMed ID: 21070842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reference tables for the intrasubject coefficient of variation in bioequivalence studies.
    Steinijans VW; Sauter R; Hauschke D; Diletti E; Schall R; Luus HG; Elze M; Blume H; Hoffmann C; Franke G
    Int J Clin Pharmacol Ther; 1995 Aug; 33(8):427-30. PubMed ID: 8556220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Challenges of developing palatable oral paediatric formulations.
    Cram A; Breitkreutz J; Desset-Brèthes S; Nunn T; Tuleu C;
    Int J Pharm; 2009 Jan; 365(1-2):1-3. PubMed ID: 18848611
    [No Abstract]   [Full Text] [Related]  

  • 25. Drug delivery and formulations.
    Breitkreutz J; Boos J
    Handb Exp Pharmacol; 2011; 205():91-107. PubMed ID: 21882107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Problems in paediatric prescribing.
    Catzel P
    Practitioner; 1976 Sep; 217(1299):396-402. PubMed ID: 981131
    [No Abstract]   [Full Text] [Related]  

  • 27. The EU paediatric regulation: effects on paediatric psychopharmacology in Europe.
    Stoyanova-Beninska VV; Wohlfarth T; Isaac M; Kalverdijk LJ; van den Berg H; Gispen-de Wied C
    Eur Neuropsychopharmacol; 2011 Aug; 21(8):565-70. PubMed ID: 20621456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physicochemical characterisation of fluids and soft foods frequently mixed with oral drug formulations prior to administration to children.
    Kersten E; Barry A; Klein S
    Pharmazie; 2016 Mar; 71(3):122-7. PubMed ID: 27183705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Are children getting the right drugs?].
    Bratlid D
    Tidsskr Nor Laegeforen; 2005 Dec; 125(23):3290-2. PubMed ID: 16327857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase transformation considerations during process development and manufacture of solid oral dosage forms.
    Zhang GG; Law D; Schmitt EA; Qiu Y
    Adv Drug Deliv Rev; 2004 Feb; 56(3):371-90. PubMed ID: 14962587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ease of oral administration and owner-perceived acceptability of triglyceride oil, dissolving thin film strip, and gelatin capsule formulations to healthy cats.
    Traas AM; Fleck T; Ellings A; Mahabir S; Stuebner K; Brown DC; Durso D; DiGregorio M; Bode L; Kievit KI; McCall R
    Am J Vet Res; 2010 Jun; 71(6):610-4. PubMed ID: 20513174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Approaches for the development of solid and semi-solid lipid-based formulations.
    Jannin V; Musakhanian J; Marchaud D
    Adv Drug Deliv Rev; 2008 Mar; 60(6):734-46. PubMed ID: 18045728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Orodispersible drug formulations for children and elderly.
    Slavkova M; Breitkreutz J
    Eur J Pharm Sci; 2015 Jul; 75():2-9. PubMed ID: 25736528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paediatric clinical trials: redressing the imbalance.
    Schreiner MS
    Nat Rev Drug Discov; 2003 Dec; 2(12):949-61. PubMed ID: 14654794
    [No Abstract]   [Full Text] [Related]  

  • 36. Barriers to administering non-oral formulations in a paediatric population: A semi-structured interview study.
    Venables R; Batchelor H; Stirling H; Marriott J
    Int J Pharm; 2016 Jan; 497(1-2):12-7. PubMed ID: 26611666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability.
    Thyssen A; Remmerie B; D'Hoore P; Kushner S; Mannaert E
    Clin Ther; 2007 Feb; 29(2):290-304. PubMed ID: 17472821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modelling approaches to dose estimation in children.
    Johnson TN
    Br J Clin Pharmacol; 2005 Jun; 59(6):663-9. PubMed ID: 15948929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acceptance of uncoated mini-tablets in young children: results from a prospective exploratory cross-over study.
    Spomer N; Klingmann V; Stoltenberg I; Lerch C; Meissner T; Breitkreutz J
    Arch Dis Child; 2012 Mar; 97(3):283-6. PubMed ID: 22253279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral dosage forms.
    Prescrire Int; 2014 Sep; 23(152):212-3. PubMed ID: 25325122
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.